Table of Contents Author Guidelines Submit a Manuscript
Infectious Diseases in Obstetrics and Gynecology
Volume 2014 (2014), Article ID 125087, 11 pages
http://dx.doi.org/10.1155/2014/125087
Review Article

Silencing Sexually Transmitted Infections: Topical siRNA-Based Interventions for the Prevention of HIV and HSV

M.D./Ph.D. Program, Harvard Medical School, Program for Cellular & Molecular Medicine, Boston Children’s Hospital, Boston, MA 02111, USA

Received 24 July 2013; Accepted 25 November 2013; Published 12 January 2014

Academic Editor: Kevin Ault

Copyright © 2014 Lee Adam Wheeler. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. J. Whitley, Field’s Virology, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2001.
  2. Centers for Disease Control and Prevention , “Seroprevalence of herpes simplex virus type 2 among persons aged 14–49 years—United States, 2005–2008,” Morbidity and Mortality Weekly Report, vol. 59, pp. 456–459, 2010. View at Google Scholar
  3. H. Weiss, “Epidemiology of herpes simplex virus type 2 infection in the developing world,” Herpes, vol. 11, supplement 1, pp. 24A–35A, 2004. View at Google Scholar · View at Scopus
  4. L. Corey, A. Wald, C. L. Celum, and T. C. Quinn, “The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics,” Journal of Acquired Immune Deficiency Syndromes, vol. 35, no. 5, pp. 435–445, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. D. M. Koelle and A. Wald, “Herpes simplex virus: the importance of asymptomatic shedding,” Journal of Antimicrobial Chemotherapy, vol. 45, supplement 3, pp. 1–8, 2000. View at Google Scholar · View at Scopus
  6. L. Corey, A. Wald, R. Patel et al., “Once-daily valacyclovir to reduce the risk of transmission of genital herpes,” The New England Journal of Medicine, vol. 350, no. 1, pp. 11–20, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. L. R. Stanberry, S. L. Spruance, A. L. Cunningham et al., “Glycoprotein-D-adjuvant vaccine to prevent genital herpes,” The New England Journal of Medicine, vol. 347, no. 21, pp. 1652–1661, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Gupta, A. Wald, E. Krantz et al., “Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract,” Journal of Infectious Diseases, vol. 190, no. 8, pp. 1374–1381, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. G. J. Mertz, O. Schmidt, and J. L. Jourden, “Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts,” Sexually Transmitted Diseases, vol. 12, no. 1, pp. 33–39, 1985. View at Google Scholar · View at Scopus
  10. A. Wald, D. Carrell, M. Remington, E. Kexel, J. Zeh, and L. Corey, “Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection,” Clinical Infectious Diseases, vol. 34, no. 7, pp. 944–948, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. P. E. Bonnar, “Suppressive valacyclovir therapy to reduce genital herpes transmission: good public health policy?” McGill Journal of Medicine, vol. 12, pp. 39–46, 2009. View at Google Scholar
  12. C. Casper and A. Wald, “Condom use and the prevention of genital herpes acquisition,” Herpes, vol. 9, no. 1, pp. 10–14, 2002. View at Google Scholar · View at Scopus
  13. A. Wald, A. G. M. Langenberg, K. Link et al., “Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women,” Journal of the American Medical Association, vol. 285, no. 24, pp. 3100–3106, 2001. View at Google Scholar · View at Scopus
  14. D. Serwadda, R. H. Gray, N. K. Sewankambo et al., “Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda,” Journal of Infectious Diseases, vol. 188, no. 10, pp. 1492–1497, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Wald and K. Link, “Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis,” Journal of Infectious Diseases, vol. 185, no. 1, pp. 45–52, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. E. E. Freeman, H. A. Weiss, J. R. Glynn, P. L. Cross, J. A. Whitworth, and R. J. Hayes, “Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies,” AIDS, vol. 20, no. 1, pp. 73–83, 2006. View at Google Scholar · View at Scopus
  17. UNAIDS, Report on the Global HIV/AIDS Epidemic 2008: Executive Summary, UNAIDS, Geneva, Switzerland, 2008.
  18. M. S. Hirsch and J. C. Kaplan, “Prospects of therapy for infections with human T-lymphotropic virus type III,” Annals of Internal Medicine, vol. 103, no. 5, pp. 750–755, 1985. View at Google Scholar · View at Scopus
  19. T. Beardsley, “AIDS progress. Synthetic vaccine only a distant prospect,” Nature, vol. 314, no. 6013, p. 659, 1985. View at Google Scholar · View at Scopus
  20. P. S. Sarma, K. J. Cremer, and J. Gruber, “Acquired immunodeficiency syndrome: progress and prospects for vaccine development,” Journal of the National Cancer Institute, vol. 80, no. 15, pp. 1193–1197, 1988. View at Google Scholar · View at Scopus
  21. W. C. Koff and D. F. Hoth, “Development and testing of AIDS vaccines,” Science, vol. 241, no. 4864, pp. 426–432, 1988. View at Google Scholar · View at Scopus
  22. H. W. Virgin and B. D. Walker, “Immunology and the elusive AIDS vaccine,” Nature, vol. 464, no. 7286, pp. 224–231, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. B. D. Walker and D. R. Burton, “Toward an AIDS vaccine,” Science, vol. 320, no. 5877, pp. 760–764, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. S. W. Lagakos and A. R. Gable, “Challenges to HIV prevention—seeking effective measures in the absence of a vaccine,” The New England Journal of Medicine, vol. 358, no. 15, pp. 1543–1545, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. E. L. Murphy, A. C. Collier, L. A. Kalish et al., “Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease,” Annals of Internal Medicine, vol. 135, no. 1, pp. 17–26, 2001. View at Google Scholar · View at Scopus
  26. V. Simon and D. D. Ho, “HIV-1 dynamics in vivo: implications for therapy,” Nature reviews. Microbiology, vol. 1, no. 3, pp. 181–190, 2003. View at Google Scholar · View at Scopus
  27. R. S. Hogg, K. V. Heath, B. Yip et al., “Improved survival among HIV-infected individuals following initiation of antiretroviral therapy,” Journal of the American Medical Association, vol. 279, no. 6, pp. 450–454, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. F. J. Palella Jr., K. M. Delaney, A. C. Moorman et al., “Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection,” The New England Journal of Medicine, vol. 338, no. 13, pp. 853–860, 1998. View at Publisher · View at Google Scholar · View at Scopus
  29. D. C. Watson and J. J. Farley, “Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1,” Pediatric Infectious Disease Journal, vol. 18, no. 8, pp. 682–689, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. M. de Martino, P.-A. Tovo, M. Balducci et al., “Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection,” Journal of the American Medical Association, vol. 284, no. 2, pp. 190–197, 2000. View at Google Scholar · View at Scopus
  31. T.-W. Chun, L. Carruth, D. Finzi et al., “Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection,” Nature, vol. 387, no. 6629, pp. 183–188, 1997. View at Publisher · View at Google Scholar · View at Scopus
  32. V. Giacomet, F. Albano, F. Starace et al., “Adherence to antiretroviral therapy and its determinants in children with human immunodeficiency virus infection: a multicentre, national study,” Acta Paediatrica, vol. 92, no. 12, pp. 1398–1402, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. M. P. Carrieri, F. Raffi, C. Lewden et al., “Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study,” Antiviral Therapy, vol. 8, no. 6, pp. 585–594, 2003. View at Google Scholar · View at Scopus
  34. D. L. Paterson, S. Swindells, J. Mohr et al., “Adherence to protease inhibitor therapy and outcomes in patients with HIV infection,” Annals of Internal Medicine, vol. 133, no. 1, pp. 21–30, 2000. View at Google Scholar · View at Scopus
  35. J. A. Epping-Jordan, R. Bengoa, R. Kawar, and E. Sabaté, “The challenge of chronic conditions: WHO responds,” British Medical Journal, vol. 323, no. 7319, pp. 947–948, 2001. View at Google Scholar · View at Scopus
  36. E. Wood, R. S. Hogg, B. Yip, P. R. Harrigan, M. V. O'Shaughnessy, and J. S. G. Montaner, “Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L,” Annals of Internal Medicine, vol. 139, no. 10, pp. 810–816, 2003. View at Google Scholar · View at Scopus
  37. I. Lanièce, M. Ciss, A. Desclaux et al., “Adherence to HAART and its principal determinants in a cohort of Senegalese adults,” AIDS, vol. 17, no. 3, pp. S103–S108, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Weiss, T. French, R. Finkelstein, M. Waters, R. Mukherjee, and B. Agins, “HIV-related knowledge and adherence to HAART,” AIDS Care, vol. 15, no. 5, pp. 673–679, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. D. A. Murphy, M. Sarr, S. J. Durako, A.-B. Moscicki, C. M. Wilson, and L. R. Muenz, “Barriers to HAART adherence among human immunodeficiency virus—infected adolescents,” Archives of Pediatrics and Adolescent Medicine, vol. 157, no. 3, pp. 249–255, 2003. View at Google Scholar · View at Scopus
  40. B. S. Peters and K. Conway, “Therapy for HIV: past, present, and future,” Advances in Dental Research, vol. 23, no. 1, pp. 23–27, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Krüsi, E. Wood, J. Montaner, and T. Kerr, “Social and structural determinants of HAART access and adherence among injection drug users,” International Journal of Drug Policy, vol. 21, no. 1, pp. 4–9, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Orsi and C. D'Almeida, “Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries,” Current Opinion in HIV and AIDS, vol. 5, no. 3, pp. 237–241, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. V. Simon, J. Vanderhoeven, A. Hurley et al., “Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals,” AIDS, vol. 16, no. 11, pp. 1511–1519, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. D. Finzi, M. Hermankova, T. Pierson et al., “Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy,” Science, vol. 278, no. 5341, pp. 1295–1300, 1997. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Zhang, B. Ramratnam, K. Tenner-Racz et al., “Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy,” The New England Journal of Medicine, vol. 340, no. 21, pp. 1605–1613, 1999. View at Publisher · View at Google Scholar · View at Scopus
  46. O. Turriziani, M. Andreoni, and G. Antonelli, “Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection,” Clinical Microbiology and Infection, vol. 16, no. 10, pp. 1518–1524, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. D. D. Ho and L. Zhang, “HIV-1 rebound after anti-retroviral therapy,” Nature Medicine, vol. 6, no. 7, pp. 736–737, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. B. Ramratnam, J. E. Mittler, L. Zhang et al., “The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy,” Nature Medicine, vol. 6, no. 1, pp. 82–85, 2000. View at Publisher · View at Google Scholar · View at Scopus
  49. F. Hladik and G. F. Doncel, “Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities,” Antiviral Research, vol. 88, supplement 1, pp. S3–S9, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. N. S. Padian, A. Buvé, J. Balkus, D. Serwadda, and W. Cates Jr., “Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward,” The Lancet, vol. 372, no. 9638, pp. 585–599, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. L. A. Paxton, T. Hope, and H. W. Jaffe, “Pre-exposure prophylaxis for HIV infection: what if it works?” The Lancet, vol. 370, no. 9581, pp. 89–93, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. K. Underhill, D. Operario, M. J. Mimiaga, M. R. Skeer, and K. H. Mayer, “Implementation science of pre-exposure prophylaxis: preparing for public Use,” Current HIV/AIDS Reports, vol. 7, no. 4, pp. 210–219, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. A. K. Sethi, D. D. Celentano, S. J. Gange, R. D. Moore, and J. E. Gallant, “Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance,” Clinical Infectious Diseases, vol. 37, no. 8, pp. 1112–1118, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. UNAIDS, “World AIDS day report 2011,” in World AIDS Day Report, UNAIDS, Geneva, Switzerland, 2011. View at Google Scholar
  55. M. J. McElrath, S. C. de Rosa, Z. Moodie et al., “HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis,” The Lancet, vol. 372, no. 9653, pp. 1894–1905, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. S. P. Buchbinder, D. V. Mehrotra, A. Duerr et al., “Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial,” The Lancet, vol. 372, no. 9653, pp. 1881–1893, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. J. Cohen, “Beyond thailand: making sense of a qualified AIDS vaccine ‘success’,” Science, vol. 326, no. 5953, pp. 652–653, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. N. Karasavvas, E. Billings, M. Rao et al., “The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120,” AIDS Research and Human Retroviruses, vol. 28, pp. 1444–1457, 2012. View at Google Scholar
  59. A. Sabchareon, D. Wallace, C. Sirivichayakul et al., “Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial,” The Lancet, vol. 380, pp. 1559–1567, 2012. View at Google Scholar
  60. T. Dudek and D. M. Knipe, “Replication-defective viruses as vaccines and vaccine vectors,” Virology, vol. 344, no. 1, pp. 230–239, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. Y. Hoshino, S. K. Dalai, K. Wang et al., “Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs,” Journal of Virology, vol. 79, pp. 410–418, 2005. View at Google Scholar
  62. J. T. Bryan, “Developing an HPV vaccine to prevent cervical cancer and genital warts,” Vaccine, vol. 25, no. 16, pp. 3001–3006, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. R. K. Zimmerman, “HPV vaccine and its recommendations, 2007,” Journal of Family Practice, vol. 56, no. 2, pp. S1–S5, 2007. View at Google Scholar · View at Scopus
  64. E. A. Joura, S. Leodolter, M. Hernandez-Avila et al., “Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials,” The Lancet, vol. 369, no. 9574, pp. 1693–1702, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. S. M. Garland, M. Hernandez-Avila, C. M. Wheeler et al., “Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases,” The New England Journal of Medicine, vol. 356, no. 19, pp. 1928–1943, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. L. R. Minces and I. McGowan, “Advances in the development of microbicides for the prevention of HIV infection,” Current Infectious Disease Reports, vol. 12, no. 1, pp. 56–62, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. J. M. Lange, M. Karam, and P. Piot, “Boost for vaginal microbicides against HIV,” The Lancet, vol. 342, no. 8883, p. 1356, 1993. View at Google Scholar · View at Scopus
  68. D. S. Nikolic, E. Garcia, and V. Piguet, “Microbicides and other topical agents in the prevention of HIV and sexually transmitted infections,” Expert Review of Anti-Infective Therapy, vol. 5, no. 1, pp. 77–88, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. A. S. Bourinbaiar and E. C. Fruhstorfer, “The efficacy of nonoxynol-9 from an in vitro point of view,” AIDS, vol. 10, no. 5, pp. 558–559, 1996. View at Google Scholar · View at Scopus
  70. M. Malkovsky, A. Newell, and A. G. Dalgleish, “Inactivation of HIV by nonoxynol-9,” The Lancet, vol. 1, no. 8586, p. 645, 1988. View at Google Scholar · View at Scopus
  71. B. C. Herold, R. Kirkpatrick, D. Marcellino et al., “Bile salts: natural detergents for the prevention of sexually transmitted diseases,” Antimicrobial Agents and Chemotherapy, vol. 43, no. 4, pp. 745–751, 1999. View at Google Scholar · View at Scopus
  72. M. K. Stafford, H. Ward, A. Flanagan et al., “Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects,” Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 17, no. 4, pp. 327–331, 1998. View at Google Scholar · View at Scopus
  73. R. E. Roddy, L. Zekeng, K. A. Ryan, U. Tamoufé, S. S. Weir, and E. L. Wong, “A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases,” The New England Journal of Medicine, vol. 339, no. 8, pp. 504–510, 1998. View at Publisher · View at Google Scholar · View at Scopus
  74. L. van Damme, G. Ramjee, M. Alary et al., “Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial,” The Lancet, vol. 360, no. 9338, pp. 971–977, 2002. View at Publisher · View at Google Scholar · View at Scopus
  75. S. L. Hillier, T. Moench, R. Shattock, R. Black, P. Reichelderfer, and F. Veronese, “In vitro and in vivo: the story of nonoxynol 9,” Journal of Acquired Immune Deficiency Syndromes, vol. 39, no. 1, pp. 1–8, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. K. H. Mayer, J. Peipert, T. Fleming et al., “Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States,” Clinical Infectious Diseases, vol. 32, no. 3, pp. 476–482, 2001. View at Publisher · View at Google Scholar · View at Scopus
  77. L. van Damme, R. Govinden, F. M. Mirembe et al., “Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission,” The New England Journal of Medicine, vol. 359, no. 5, pp. 463–472, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. M. J. Keller, A. Tuyama, M. J. Carlucci, and B. C. Herold, “Topical microbicides for the prevention of genital herpes infection,” Journal of Antimicrobial Chemotherapy, vol. 55, no. 4, pp. 420–423, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. I. McGowan, “Microbicides for HIV prevention: reality or hope?” Current Opinion in Infectious Diseases, vol. 23, no. 1, pp. 26–31, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. Q. A. Karim, S. S. A. Karim, J. A. Frohlich et al., “Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women,” Science, vol. 329, no. 5996, pp. 1168–1174, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. I. McGowan, “Rectal microbicide development,” Current Opinion in HIV and AIDS, vol. 7, pp. 526–533, 2012. View at Google Scholar
  82. P. A. Anton, R. D. Cranston, A. Kashuba et al., “RMP-02/MTN-006: a phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate,” AIDS Research and Human Retroviruses, vol. 28, pp. 1412–1421, 2012. View at Google Scholar
  83. C. Celum and J. M. Baeten, “Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence,” Current Opinion in Infectious Diseases, vol. 25, no. 1, pp. 51–57, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. S. M. Elbashir, J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl, “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells,” Nature, vol. 411, no. 6836, pp. 494–498, 2001. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Fire, S. Xu, M. K. Montgomery, S. A. Kostas, S. E. Driver, and C. C. Mello, “Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans,” Nature, vol. 391, no. 6669, pp. 806–811, 1998. View at Publisher · View at Google Scholar · View at Scopus
  86. R. Jorgensen, “Altered gene expression in plants due to trans interactions between homologous genes,” Trends in Biotechnology, vol. 8, no. 12, pp. 340–344, 1990. View at Google Scholar · View at Scopus
  87. B. Wightman, I. Ha, and G. Ruvkun, “Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans,” Cell, vol. 75, no. 5, pp. 855–862, 1993. View at Publisher · View at Google Scholar · View at Scopus
  88. R. C. Lee, R. L. Feinbaum, and V. Ambros, “The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14,” Cell, vol. 75, no. 5, pp. 843–854, 1993. View at Publisher · View at Google Scholar · View at Scopus
  89. C. D. Novina, M. F. Murray, D. M. Dykxhoorn et al., “siRNA-directed inhibition of HIV-1 infection,” Nature Medicine, vol. 8, pp. 681–686, 2002. View at Google Scholar
  90. S.-K. Lee, D. M. Dykxhoorn, P. Kumar et al., “Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV,” Blood, vol. 106, no. 3, pp. 818–826, 2005. View at Publisher · View at Google Scholar · View at Scopus
  91. P. Kumar, H.-S. Ban, S.-S. Kim et al., “T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice,” Cell, vol. 134, no. 4, pp. 577–586, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. E. Song, S.-K. Lee, D. M. Dykxhoorn et al., “Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages,” Journal of Virology, vol. 77, no. 13, pp. 7174–7181, 2003. View at Publisher · View at Google Scholar · View at Scopus
  93. E. Song, P. Zhu, S.-K. Lee et al., “Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors,” Nature Biotechnology, vol. 23, no. 6, pp. 709–717, 2005. View at Publisher · View at Google Scholar · View at Scopus
  94. V. Bitko, A. Musiyenko, O. Shulyayeva, and S. Barik, “Inhibition of respiratory viruses by nasally administered siRNA,” Nature Medicine, vol. 11, no. 1, pp. 50–55, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. D. Palliser, D. Chowdhury, Q.-Y. Wang et al., “An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection,” Nature, vol. 439, no. 7072, pp. 89–94, 2006. View at Publisher · View at Google Scholar · View at Scopus
  96. Y. Wu, F. Navarro, A. Lal et al., “Durable protection from herpes simplex virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene,” Cell Host and Microbe, vol. 5, no. 1, pp. 84–94, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. D. Peer, J. P. Eun, Y. Morishita, C. V. Carman, and M. Shimaoka, “Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target,” Science, vol. 319, no. 5863, pp. 627–630, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. D. Peer, P. Zhu, C. V. Carman, J. Lieberman, and M. Shimaoka, “Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 10, pp. 4095–4100, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. E. Song, S.-K. Lee, J. Wang et al., “RNA interference targeting Fas protects mice from fulminant hepatitis,” Nature Medicine, vol. 9, no. 3, pp. 347–351, 2003. View at Publisher · View at Google Scholar · View at Scopus
  100. P. Hamar, E. Song, G. Kökeny, A. Chen, N. Ouyang, and J. Lieberman, “Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 41, pp. 14883–14888, 2004. View at Publisher · View at Google Scholar · View at Scopus
  101. D. M. Dykxhoorn, D. Chowdhury, and J. Lieberman, “RNA interference and cancer: endogenous pathways and therapeutic approaches,” Advances in Experimental Medicine and Biology, vol. 615, pp. 299–329, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. S. I. Pai, Y.-Y. Lin, B. Macaes, A. Meneshian, C.-F. Hung, and T.-C. Wu, “Prospects of RNA interference therapy for cancer,” Gene Therapy, vol. 13, no. 6, pp. 464–477, 2006. View at Publisher · View at Google Scholar · View at Scopus
  103. T. R. Brummelkamp, R. Bernards, and R. Agami, “Stable suppression of tumorigenicity by virus-mediated RNA interference,” Cancer Cell, vol. 2, no. 3, pp. 243–247, 2002. View at Publisher · View at Google Scholar · View at Scopus
  104. D. H. Kim and J. J. Rossi, “RNAi mechanisms and applications,” BioTechniques, vol. 44, no. 5, pp. 613–616, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. L. A. Wheeler and D. M. Dykxhoorn, “RNAi as a potential new therapy for HIV infection,” Future HIV Therapy, vol. 2, no. 6, pp. 567–577, 2008. View at Publisher · View at Google Scholar · View at Scopus
  106. D. S. Schwarz, G. Hutvágner, T. Du, Z. Xu, N. Aronin, and P. D. Zamore, “Asymmetry in the assembly of the RNAi enzyme complex,” Cell, vol. 115, no. 2, pp. 199–208, 2003. View at Publisher · View at Google Scholar · View at Scopus
  107. C. Matranga, Y. Tomari, C. Shin, D. P. Bartel, and P. D. Zamore, “Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes,” Cell, vol. 123, no. 4, pp. 607–620, 2005. View at Publisher · View at Google Scholar · View at Scopus
  108. D. M. Dykxhoorn and J. Lieberman, “Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs,” Annual Review of Biomedical Engineering, vol. 8, pp. 377–402, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004. View at Publisher · View at Google Scholar · View at Scopus
  110. G. Stefani and F. J. Slack, “Small non-coding RNAs in animal development,” Nature Reviews Molecular Cell Biology, vol. 9, no. 3, pp. 219–230, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. L. Wu and J. G. Belasco, “Let Me count the ways: mechanisms of gene regulation by miRNAs and siRNAs,” Molecular Cell, vol. 29, no. 1, pp. 1–7, 2008. View at Publisher · View at Google Scholar · View at Scopus
  112. A. de Fougerolles, H.-P. Vornlocher, J. Maraganore, and J. Lieberman, “Interfering with disease: a progress report on siRNA-based therapeutics,” Nature Reviews Drug Discovery, vol. 6, no. 6, pp. 443–453, 2007. View at Publisher · View at Google Scholar · View at Scopus
  113. B. Berkhout and O. Ter Brake, “Towards a durable RNAi gene therapy for HIV-AIDS,” Expert Opinion on Biological Therapy, vol. 9, no. 2, pp. 161–170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  114. J. Capodici, K. Karikó, and D. Weissman, “Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference,” Journal of Immunology, vol. 169, no. 9, pp. 5196–5201, 2002. View at Google Scholar · View at Scopus
  115. G. A. Coburn and B. R. Cullen, “Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference,” Journal of Virology, vol. 76, no. 18, pp. 9225–9231, 2002. View at Publisher · View at Google Scholar · View at Scopus
  116. J.-M. Jacque, K. Triques, and M. Stevenson, “Modulation of HIV-1 replication by RNA interference,” Nature, vol. 418, no. 6896, pp. 435–438, 2002. View at Publisher · View at Google Scholar · View at Scopus
  117. N. S. Lee, T. Dohjima, G. Bauer et al., “Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells,” Nature Biotechnology, vol. 20, no. 5, pp. 500–505, 2002. View at Publisher · View at Google Scholar · View at Scopus
  118. A. L. Brass, D. M. Dykxhoorn, Y. Benita et al., “Identification of host proteins required for HIV infection through a functional genomic screen,” Science, vol. 319, no. 5865, pp. 921–926, 2008. View at Publisher · View at Google Scholar · View at Scopus
  119. Y. Gao, M. A. Lobritz, J. Roth et al., “Targets of small interfering RNA restriction during human immunodeficiency virus type 1 replication,” Journal of Virology, vol. 82, no. 6, pp. 2938–2951, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. R. Alvarez, S. Elbashir, T. Borland et al., “RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 9, pp. 3952–3962, 2009. View at Publisher · View at Google Scholar · View at Scopus
  121. W. Zhang, H. Yang, X. Kong et al., “Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene,” Nature Medicine, vol. 11, no. 1, pp. 56–62, 2005. View at Publisher · View at Google Scholar · View at Scopus
  122. L. A. Wheeler, V. Vrbanac, R. Trifonova et al., “Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras,” Molecular Therapy, vol. 21, pp. 1378–1389, 2013. View at Google Scholar
  123. L. A. Wheeler, R. Trifonova, V. Vrbanac et al., “Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras,” Journal of Clinical Investigation, vol. 121, no. 6, pp. 2401–2412, 2011. View at Publisher · View at Google Scholar · View at Scopus
  124. R. M. Grant, D. Hamer, T. Hope et al., “Whither or wither microbicides?” Science, vol. 321, no. 5888, pp. 532–534, 2008. View at Publisher · View at Google Scholar · View at Scopus
  125. J. Yano, K. Hirabayashi, S.-I. Nakagawa et al., “Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer,” Clinical Cancer Research, vol. 10, no. 22, pp. 7721–7726, 2004. View at Publisher · View at Google Scholar · View at Scopus
  126. J. Anderson, A. Banerjea, V. Planelles, and R. Akkina, “Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA,” AIDS Research and Human Retroviruses, vol. 19, no. 8, pp. 699–706, 2003. View at Publisher · View at Google Scholar · View at Scopus
  127. E. Devroe and P. A. Silver, “Therapeutic potential of retroviral RNAi vectors,” Expert Opinion on Biological Therapy, vol. 4, no. 3, pp. 319–327, 2004. View at Publisher · View at Google Scholar · View at Scopus
  128. D. L. Lewis and J. A. Wolff, “Delivery of siRNA and siRNA expression constructs to adult mammals by hydrodynamic intravascular injection,” Methods in Enzymology, vol. 392, pp. 336–350, 2005. View at Publisher · View at Google Scholar · View at Scopus
  129. C. Lorenz, P. Hadwiger, M. John, H.-P. Vornlocher, and C. Unverzagt, “Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells,” Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 19, pp. 4975–4977, 2004. View at Publisher · View at Google Scholar · View at Scopus
  130. Y. Minakuchi, F. Takeshita, N. Kosaka et al., “Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo,” Nucleic Acids Research, vol. 32, no. 13, p. e109, 2004. View at Google Scholar · View at Scopus
  131. J. Soutschek, A. Akinc, B. Bramlage et al., “Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs,” Nature, vol. 432, no. 7014, pp. 173–178, 2004. View at Publisher · View at Google Scholar · View at Scopus
  132. B. Urban-Klein, S. Werth, S. Abuharbeid, F. Czubayko, and A. Aigner, “RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo,” Gene Therapy, vol. 12, no. 5, pp. 461–466, 2005. View at Publisher · View at Google Scholar · View at Scopus
  133. R. A. Stull and F. C. Szoka Jr., “Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects,” Pharmaceutical Research, vol. 12, no. 4, pp. 465–483, 1995. View at Google Scholar · View at Scopus
  134. L. Scherer, J. J. Rossi, and M. S. Weinberg, “Progress and prospects: RNA-based therapies for treatment of HIV infection,” Gene Therapy, vol. 14, no. 14, pp. 1057–1064, 2007. View at Publisher · View at Google Scholar · View at Scopus
  135. D. M. Held, J. D. Kissel, J. T. Patterson, D. G. Nickens, and D. H. Burke, “HIV-1 inactivation by nucleic acid aptamers,” Frontiers in Bioscience, vol. 11, no. 1, pp. 89–112, 2006. View at Google Scholar · View at Scopus
  136. J. O. McNamara II, E. R. Andrechek, Y. Wang et al., “Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras,” Nature Biotechnology, vol. 24, no. 8, pp. 1005–1015, 2006. View at Publisher · View at Google Scholar · View at Scopus
  137. J. P. Dassie, X.-Y. Liu, G. S. Thomas et al., “Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors,” Nature Biotechnology, vol. 27, no. 9, pp. 839–846, 2009. View at Publisher · View at Google Scholar · View at Scopus
  138. J. Zhou, H. Li, S. Li, J. Zaia, and J. J. Rossi, “Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy,” Molecular Therapy, vol. 16, no. 8, pp. 1481–1489, 2008. View at Publisher · View at Google Scholar · View at Scopus
  139. J. Zhou, P. Swiderski, H. Li et al., “Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells,” Nucleic Acids Research, vol. 37, no. 9, pp. 3094–3109, 2009. View at Publisher · View at Google Scholar · View at Scopus
  140. C. P. Neff, J. Zhou, L. Remling et al., “An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4+ T cell decline in humanized mice,” Science Translational Medicine, vol. 3, no. 66, Article ID 66ra6, 2011. View at Publisher · View at Google Scholar · View at Scopus
  141. D. M. Brainard, E. Seung, N. Frahm et al., “Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice,” Journal of Virology, vol. 83, no. 14, pp. 7305–7321, 2009. View at Publisher · View at Google Scholar · View at Scopus
  142. J. Zhou, H. Li, J. Zhang, S. Piotr, and J. Rossi, “Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery,” Journal of Visualized Experiments, no. 52, Article ID e2954, 2011. View at Publisher · View at Google Scholar · View at Scopus
  143. OPKO Health, “OPKO Health announces update on Phase III clinical trial of bevasiranib,” Press release.
  144. M. Robbins, A. Judge, and I. MacLachlan, “SiRNA and innate immunity,” Oligonucleotides, vol. 19, no. 2, pp. 89–102, 2009. View at Publisher · View at Google Scholar · View at Scopus
  145. J. A. Katakowski and D. Palliser, “SiRNA-based topical microbicides targeting sexually transmitted infections,” Current Opinion in Molecular Therapeutics, vol. 12, no. 2, pp. 192–202, 2010. View at Google Scholar · View at Scopus
  146. V. Hornung, M. Guenthner-Biller, C. Bourquin et al., “Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7,” Nature Medicine, vol. 11, no. 3, pp. 263–270, 2005. View at Publisher · View at Google Scholar · View at Scopus
  147. A. D. Judge, V. Sood, J. R. Shaw, D. Fang, K. McClintock, and I. MacLachlan, “Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA,” Nature Biotechnology, vol. 23, no. 4, pp. 457–462, 2005. View at Publisher · View at Google Scholar · View at Scopus
  148. M. Robbins, A. Judge, E. Ambegia et al., “Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation,” Human Gene Therapy, vol. 19, no. 10, pp. 991–999, 2008. View at Publisher · View at Google Scholar · View at Scopus
  149. M. Schlee, V. Hornung, and G. Hartmann, “siRNA and isRNA: two edges of one sword,” Molecular Therapy, vol. 14, no. 4, pp. 463–470, 2006. View at Publisher · View at Google Scholar · View at Scopus
  150. H. Poeck, R. Besch, C. Maihoefer et al., “5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma,” Nature Medicine, vol. 14, no. 11, pp. 1256–1263, 2008. View at Publisher · View at Google Scholar · View at Scopus
  151. A. L. Jackson, J. Burchard, D. Leake et al., “Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing,” RNA, vol. 12, no. 7, pp. 1197–1205, 2006. View at Publisher · View at Google Scholar · View at Scopus
  152. K. Ui-Tei, Y. Naito, S. Zenno et al., “Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect,” Nucleic Acids Research, vol. 36, no. 7, pp. 2136–2151, 2008. View at Publisher · View at Google Scholar · View at Scopus
  153. M. B. Laursen, M. M. Pakula, S. Gao et al., “Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo,” Molecular BioSystems, vol. 6, no. 5, pp. 862–870, 2010. View at Publisher · View at Google Scholar · View at Scopus
  154. Y.-L. Chiu and T. M. Rana, “RNAi in human cells: basic structural and functional features of small interfering RNA,” Molecular Cell, vol. 10, no. 3, pp. 549–561, 2002. View at Publisher · View at Google Scholar · View at Scopus
  155. M. E. Kleinman, K. Yamada, A. Takeda et al., “Sequence- and target-independent angiogenesis suppression by siRNA via TLR3,” Nature, vol. 452, no. 7187, pp. 591–597, 2008. View at Publisher · View at Google Scholar · View at Scopus
  156. T. S. Zimmermann, A. C. H. Lee, A. Akinc et al., “RNAi-mediated gene silencing in non-human primates,” Nature, vol. 441, no. 1, pp. 111–114, 2006. View at Publisher · View at Google Scholar · View at Scopus
  157. A. A. Khan, D. Betel, M. L. Miller, C. Sander, C. S. Leslie, and D. S. Marks, “Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs,” Nature Biotechnology, vol. 27, no. 6, pp. 549–555, 2009. View at Publisher · View at Google Scholar · View at Scopus
  158. D. Grimm, K. L. Streetz, C. L. Jopling et al., “Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways,” Nature, vol. 441, no. 7092, pp. 537–541, 2006. View at Publisher · View at Google Scholar · View at Scopus
  159. M. John, R. Constien, A. Akinc et al., “Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway,” Nature, vol. 449, no. 7163, pp. 745–747, 2007. View at Publisher · View at Google Scholar · View at Scopus
  160. J. L. McBride, R. L. Boudreau, S. Q. Harper et al., “Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 15, pp. 5868–5873, 2008. View at Publisher · View at Google Scholar · View at Scopus
  161. A. D. Judge, G. Bola, A. C. H. Lee, and I. MacLachlan, “Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo,” Molecular Therapy, vol. 13, no. 3, pp. 494–505, 2006. View at Publisher · View at Google Scholar · View at Scopus
  162. D. Castanotto, K. Sakurai, R. Lingeman et al., “Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC,” Nucleic Acids Research, vol. 35, no. 15, pp. 5154–5164, 2007. View at Publisher · View at Google Scholar · View at Scopus
  163. A. R. de Fougerolles, “Delivery vehicles for small interfering RNA in vivo,” Human Gene Therapy, vol. 19, no. 2, pp. 125–132, 2008. View at Publisher · View at Google Scholar · View at Scopus
  164. B. L. Davidson and P. B. McCray Jr., “Current prospects for RNA interference-based therapies,” Nature Reviews Genetics, vol. 12, no. 5, pp. 329–340, 2011. View at Publisher · View at Google Scholar · View at Scopus